neuroClues team picture at iPEPS ICM Paris

NeuroClues™ (P3Lab) awarded funding from the European Commission through the prestigious EIC Accelerator Program

In summary

  • P3Lab is one of the 78 companies selected among 1092 applicants by the European program EIC Accelerator.
  • The funds will enable the company to accelerate the go-to-market of neuroCluesTM, the all-in-one eye tracking solution that will empower clinicians with Biomarkers allowing them to identify Neurological Disorders years before visible symptoms.
  • P3Lab rebrands as neuroClues™, to align our identity with our ambition to deliver diagnostic and prognostic solutions for Neurological Disorders clinicians around the world.

Louvain-la-Neuve, Belgium, 19 December 2022 – P3Lab announced today it has been awarded blended funding, of which a €2.5 million grant, by the European Commission under the highly selective EIC Accelerator program.

In a world where neurological disorders will affect 1 person in 3 and where the number of Parkinson’s patients will double in the next decade, reaching 13 million patients, P3Lab’s mission is to empower clinicians with biomarkers allowing them to identify neurological disorders (Parkinson’s Disease, Alzheimer’s Disease, and Multiple Sclerosis) years before visible symptoms.

This grant will allow the company to demonstrate the clinical relevance of NeuroClues in the diagnosis of Parkinson’s Disease and roll-out its marketing & commercial strategy in the European Union and in the United States.

Antoine Pouppez, Chief Executive Officer of P3Lab, commented: “We are delighted that P3Lab has been singled out by the European Commission after an extremely selective process. This recognition by European Experts illustrates our commitment to support our patients and clinicians dealing with neurological disorders. NeuroClues will give them access to biomarkers to help them diagnose and prognose Parkinson’s Disease.  The support validates our technology and our ambitious approach, recognising the strong value created in the past 2 years. I am very proud to share this success with the whole team at P3lab, with our family, with our early investors and with the international community of clinicians who have been by our side since the beginning.”

P3Lab also announces today that it will be rebranded as “neuroClues”, eying and focusing its activities on the development of the neurological biomarkers market. With this strategic vision in mind, the goal will be to support over 10 millions patients by 2030. More information on

About the European Innovation Council: The European Innovation Council is Europe’s flagship innovation programme to identify, develop and scale up breakthrough technologies and game changing innovations The EIC has been established under the EU Horizon Europe programme. It has a budget of €10.1 billion to support game changing innovations throughout the lifecycle from early stage research, to proof of concept, technology transfer, and the financing and scale up of start-ups and SMEs.

About neuroClues: neuroClues by P3Lab is a team of researchers, doctors & engineers, inspired by science and passionate about the benefits that eye tracking can bring to health practitioners during their everyday work. Incorporated in July 2020, it is developing pragmatic healthcare solutions, starting with a mobile eye tracking laboratory. More information :

For more information, please contact


Are you enthusiastic about NeuroCluesTM and want to share it with your colleagues?

Refer them to us through this email or our LinkedIn page and we’ll be happy to have a chat.

Book a virtual demo

Book a custom virtual walk-through of NeuroClues with one of our experts and see how our innovative eye-tracking technology could impact your clinical practice.